Community-Driven Substance Use Recovery Study

This study is looking at ways to improve access to and engagement in Medication Assisted Treatment (MAT) for people in communities with high rates of opioid overdose. It's testing two approaches: IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. IMANI is a faith-based recovery program. You might be able to join if you are 18 or older, have an Alcohol Use Disorder or Opioid Use Disorder, have used alcohol or opioids in the last 28 days, want to reduce your substance use, and live in an area with high overdose rates. The study aims to see how well people attend the program and stick with their treatment over 6 months. The current recruitment status is unclear, but the study plans to enroll 525 participants.

Study design
This interventional study plans to enroll 525 participants and compares two different approaches to Medication Assisted Treatment (MAT).
What's involved
Participants will engage in the IMANI program and potentially receive MAT, with treatment adherence measured at baseline and 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants' treatment adherence will be measured at 6 months, and overall program attendance will be measured for up to 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05260047

Community Driven Substance Use Recovery for High Opioid Overdose Areas

Active, Not Recruiting
NAAges 18+InterventionalTreatment
Yale University
~525 participants
Updated 2026-06-08 on ClinicalTrials.gov
What's tested:IMANITelehealth MATTraditional MAT plus Referral and Linkage

At a glance

Recruiting sites
0 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall attendance of program
Measured over Up to 24 weeks
+3 more outcomes measured
Substance Use
Mental Health Issue
Opioid Use
Medication Assisted Treatment
8 sites across 1 states
Connecticut8
  • Chyrell Bellamy, Ph.D. · PRINCIPAL_INVESTIGATOR · Yale University
  • Ayana Jordan, PhD. · PRINCIPAL_INVESTIGATOR · Yale University

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must meet criteria for a DSM-5 Alcohol Use Disorder and/or Opioid Use Disorder and are currently using alcohol and/or other opioids within the last 28 days.
Are interested in reducing substance use.
Self-identify as living in a geographical area with high overdose case rates
  • Overall attendance of programUp to 24 weeks

    The total number of sessions that participants attend will be used to measure continuation of program.

  • Overall treatment adherenceBaseline

    The number of participants that adhere to treatments will be measured using self-report at three time points.

  • Overall treatment adherence6-month

    The number of participants that adhere to treatments will be measured using self-report at three time points.

  • Overall treatment adherence12-month

    The number of participants that adhere to treatments will be measured using self-report at three time points.